18.12.2017
PHARMASYNTEZ IS THE LAUREATE OF NATIONAL RATING OF RUSSIAN HIGH-TECH FASTEST-GROWING COMPANIES "TECHUSPEKH-2017"
On December 12, 2017, winners of the 6th annual National Rating of Russian High-Tech fastest-growing companies "TechUspekh-2017" organized by RVC have been announced.
«TechUspekh's participants become more effective every year, innovations remain their main driver, the share of small high-tech companies is growing significantly. In 2016, the TechUspekh rating became an official tool to select companies for the priority project of the Ministry of Economic Development "National Champions" aimed at supporting the strategy of accelerated development. In 2018, the rating can form the basis of the search engine to select promising companies for global NTI markets. We plan to continue active interaction with the rating participants - to support them under the NTI, offer investment tools, help interact with state corporations and development institutions," commented Alexander Povalko, RVC CEO.
To be eligible for TechUspekh rating, the participant must be a private high-tech company with at least 4 years of operation experience and showing an average annual rate of revenue growth of at least 10% -20% over the last 5 years and with last year' revenue from 100 million to 30 billion rubles. The company’s R&D expenses should not be less than 5% over the last three years, and expenses on technological innovation — at least 10%. Moreover, the share of new or significantly improved products should be at least 20-30% of the company's total revenue.
To be eligible for TechUspekh rating, the participant must be a private high-tech company with at least 4 years of operation experience and showing an average annual rate of revenue growth of at least 10% -20% over the last 5 years and with last year' revenue from 100 million to 30 billion rubles. The company’s R&D expenses should not be less than 5% over the last three years, and expenses on technological innovation — at least 10%. Moreover, the share of new or significantly improved products should be at least 20-30% of the company's total revenue.